REGN-COV2 combines 2 virus-neutralizing monoclonal antibodies that are used against SARS-CoV-2: casirivimab and imdevimab (CAS-IMD).
The CADTH Technology Review evaluated a published interim analysis of a randomized controlled trial of 2 different doses of CAS-IMD in 275 ambulatory adult patients with confirmed SARS-CoV-2 infection.
Link to Report
Casirivimab-Imdevimab for COVID-19: Evidence Review and Appraisal
Was this site helpful?
If you couldn’t find what you are looking for, please submit a request.